<DOC>
	<DOCNO>NCT01399580</DOCNO>
	<brief_summary>Prospective , Randomized , Double-Blind , Parallel Design , Placebo-Controlled Multicenter Study . The study objective evaluate efficacy safety , include thoracic bioimpedance , daily administration atrasentan tablet ( high dose low dose ) compare placebo type 2 diabetic subject nephropathy receive maximum tolerate labeled daily dose RAS inhibitor .</brief_summary>
	<brief_title>A Prospective , Double-Blind , Placebo-Controlled , Multicenter Study Evaluate Efficacy Safety Atrasentan , Including Thoracic Bioimpedance , Type 2 Diabetic Subjects With Nephropathy</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<mesh_term>Endothelin Receptor Antagonists</mesh_term>
	<mesh_term>Atrasentan</mesh_term>
	<criteria>1 . Subject great equal 18 year old . 2 . Subject type 2 diabetes treat least one antihyperglycemic medication within 12 month prior Screening Period . 3 . Subject currently receive angiotensin convert enzyme inhibitor ( ACEi ) Angiotensin II receptor blocker ( ARB ) ( Renin Angiotensin System ( RAS ) inhibitor ) . 4 . If female , subject breastfeeding pregnant ( verified negative serum pregnancy test prior Treatment Period ) . Subject childbearing potential , defined postmenopausal least one year surgically sterile ( bilateral tubal ligation , bilateral oophorectomy hysterectomy ) childbearing potential practice one approve method birth control define Clinical Trial Protocol . Contraception must use study 4 week last dose study drug . 5 . For entry Runin Period subject must satisfy follow criterion base Screening laboratory value : Estimated glomerular filtration rate ( eGFR ) great equal 30 less equal 75 mL/min/1.73m^2 Epidemiology Collaboration ( EPI ) formula Urinary Albumin Creatinine Ratio ( UACR ) great equal 300 less equal 3500 mg/g determine geometric mean two morning void urine specimen obtain Screening visit Serum albumin great equal 3.0 g/dL BType Natriuretic Peptide ( BNP ) less equal 200 pg/mL Negative serum pregnancy test female subject Systolic Blood Pressure ( SBP ) great equal 110 mmHg less equal 180 mmHg Glucosylated hemoglobin ( HbA1c ) less equal 12 % 6 . For entry Treatment Period subject must satisfy follow criterion base last visit Runin Period laboratory value : Renin Angiotensin System ( RAS ) inhibitor maximum tolerate label dose previous 4 week adjustment dose Diuretic dose unless medically contraindicate ( exception loop diuretic great equal 120 mg QD furosemide great equal 3.0 mg QD bumetanide great equal 150 mg QD ethacrynic acid great equal 60 mg QD torasemide ) UACR â‰¥ 200 mg/g determine median three morning void urine specimen obtain prior Week 1 visit Systolic Blood Pressure ( SBP ) great equal 110 mmHg less equal 160 mmHg Serum Potassium less equal 5.5 mEq/L Negative serum pregnancy test female subject 1 . Patient history moderate severe edema , facial edema unrelated trauma , history myxedema prior 6 month Screening . 2 . Subject receive loop diuretic great equal 120 mg QD furosemide great equal 3.0 mg QD bumetanide great equal 150 mg QD ethacrynic acid great equal 60 mg QD torasemide . 3 . Subject history pulmonary edema . 4 . Subject history pulmonary hypertension , lung disease require oxygen therapy ( i.e. , chronic obstructive pulmonary disease , emphysema , pulmonary fibrosis ) . 5 . Subject history orthostatic hypotension within past 6 month define presence supinetostanding blood pressure decrease great equal 20 mmHg systolic great equal 10 mmHg diastolic within 3 minute stand .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>endothelin receptor antagonist</keyword>
</DOC>